Leading the Way in Life Science Technologies

GEN Exclusives

More »

GEN News Highlights

More »
Jul 13, 2007

Pharming Sites Obtain GMP Status for Production of Drug against Hereditary Angioedema

  • Pharming reports that its facilities for the manufacturing of Rhucin® have successfully passed the EMEA’s inspections. The drug is being developed to treat acute attacks of hereditary angioedema.

    The EMEA has confirmed that all sites and processes that are involved in the manufacturing of Rhucin®, Pharming’s lead product, operate according to GMP standards. This includes the company’s buildings for transgenic rabbits, external facilities where milk and product are stored and processed, and the headquarters in Leiden as far as it is concerned with quality aspects of Rhucin.

    “Obtaining the GMP status for our facilities and processes is testimony to the hard and excellent work that our team has put in to convert a research idea of ‘turning milk into medicine’ into a well developed and GMP-approved manufacturing process. Our transgenic rabbit facility is the first of its kind in the world to obtain this status,” says Bruno Giannetti, COO at  Pharming.

    Rhucin (recombinant human C1 esterase inhibitor) is a human protein developed through Pharming’s technology in milk of transgenic rabbits. The disease is caused by a shortage of functional C1 esterase inhibitor in patients and results in an over reaction of the immune system.



Be sure to take the GEN Poll

Scientifically Studying Ecstasy

MDMA (commonly known as the empathogen “ecstasy”) is classified as a Schedule 1 drug, which is reserved for compounds with no accepted medical use and a high abuse potential. Two researchers from Stanford, however, call for a rigorous scientific exploration of MDMA's effects to identify precisely how the drug works, the data from which could be used to develop therapeutic compounds.

Do you agree that ecstasy should be studied for its potential therapeutic benefits?

More »